Data compiled by Redley Lamar · ChainSifter Intelligence
4Suppliers
13Customers
1Debt Items
19Related Chains
Source-Backed Evidence Depth
Kazia Therapeutics Limited (KZIA) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
18Total relationships
2Distinct source URLs
9High confidence
0.768Average confidence
2026-10-28Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Kazia Therapeutics Limited Suppliers
Ticker
Name
Confidence
Evidence
THIRD-PARTY-CONTRACT-MANUFACTURING-ORGANIZATIONS
THIRD-PARTY-CONTRACT-MANUFACTURING-ORGANIZATIONS
92%
The Company relies on third-party contract manufacturing organizations to manufacture its drug product candidates.
CONTRACT-FACILITIES
CONTRACT-FACILITIES
90%
The Company uses contract facilities that are registered with the FDA, have a track record of large-scale API manufacture, and have already invested in capital and equipment.
VENDORS
VENDORS
85%
If one or more of these vendors were unable to meet the Company’s needs, it may materially and adversely impact our business.
Reciprocal relationship from PPCB graph: novel expression system and are also in the process of optimizing conditions to achieve high titers of recombinant trypsinogen and chymotrypsinogen. Further, …
Kazia Therapeutics Limited Customers
Ticker
Name
Confidence
Evidence
MICHAEL-J-FOX-FOUNDATION
MICHAEL-J-FOX-FOUNDATION
92%
In fiscal year 2025, the Company received a grant of A$42 thousand from the sale of Paxalisib to the Michael J Fox Foundation to explore the therapeutic potential of Paxalisib as a treatment for Park…
BDO-AUDIT-PTY-LTD
BDO-AUDIT-PTY-LTD
85%
uation involved auditor judgment due to the nature and extent of audit effort required to address these matters, including the extent of specialized skill or knowledge needed. The primary procedures …
Reciprocal relationship from EVO graph: Reciprocal relationship from KZIA graph: Reciprocal relationship from EVO graph: Reciprocal relationship from KZIA graph: Reciprocal relationship from EVO grap…
SOVARGEN-CO-LTD
SOVARGEN-CO-LTD
85%
or the years ended 30 June 2025, 2024, and 2023, no contract milestones were met, therefore no revenue was recognized. License Agreement with Sovargen Co Ltd. In March 2024, the Company entered into …
CUSTOMERS
CUSTOMERS
80%
Increases in manufacturing costs could adversely affect the Company’s future profitability if it was unable to pass all of the increased costs along to its customers.
pate will be required to complete clinical development of a product candidate or if we experience significant delays in enrollment in any of our clinical trials, we could be required to expend signif…
Reciprocal relationship from CLRB graph: Reciprocal relationship from KZIA graph: Reciprocal relationship from CLRB graph: Reciprocal relationship from KZIA graph: Reciprocal relationship from CLRB g…
Reciprocal relationship from PPCB graph: Reciprocal relationship from KZIA graph: Reciprocal relationship from PPCB graph: novel expression system and are also in the process of optimizing conditions…
Reciprocal relationship from ANTX graph: Reciprocal relationship from KZIA graph: Reciprocal relationship from ANTX graph: Reciprocal relationship from KZIA graph: Reciprocal relationship from ANTX g…
GLIOBLAST-PTY-LTD
GLIOBLAST-PTY-LTD
62%
ry information about the parent entity. Parent 2024 A$’000 2023 A$’000 Statement of profit or loss and other comprehensive income Loss after income tax ( 24,008 ) ( 20,863 ) Total comprehensive loss …
GRANT-THORNTON-AUDIT-PTY-LTD
GRANT-THORNTON-AUDIT-PTY-LTD
62%
al reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion. Our audit inclu…
NASDAQ-STOCK-MARKET-LLC
NASDAQ-STOCK-MARKET-LLC
62%
costs could adversely affect the Company’s future profitability if it was unable to pass all of the increased costs along to its customers. The Company relies on third-party contract manufacturing or…
SIMCERE-PHARMACEUTICAL-GROUP-LTD
SIMCERE-PHARMACEUTICAL-GROUP-LTD
62%
ned useful life is the remaining life of the patent over the asset, unless other factors over-ride this assessment. Impairment of licensing agreements and other indefinite life intangible assets The …
Kazia Therapeutics Limited Debt Obligations
Instrument
Description
Confidence
Evidence
KZIA-DEBT
Debt stack $71,002
90%
Market cache reports total debt of $71,002.
Kazia Therapeutics Limited Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Kazia Therapeutics Limited.
Kazia Therapeutics Limited Ownership
No ownership data on recordNo major institutional ownership relationships found in our database for Kazia Therapeutics Limited.
